How Letrozole Benefits Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
Letrozole dramatically reduces breast cancer recurrence and improves disease-free survival in postmenopausal women with estrogen receptor-positive breast cancer by suppressing estrogen production by 75-95%, effectively starving hormone-dependent cancer cells. 1
Mechanism of Action
Letrozole works by blocking the aromatase enzyme, which is the primary source of estrogen in postmenopausal women 1. In postmenopausal women, the ovaries no longer produce estrogen; instead, the aromatase enzyme converts adrenal androgens (androstenedione and testosterone) into estrone and estradiol in peripheral tissues and within breast cancer tissue itself 1.
By competitively binding to the cytochrome P450 subunit of the aromatase enzyme, letrozole reduces estrogen biosynthesis in all tissues, achieving 75-95% suppression of plasma estradiol, estrone, and estrone sulfate within 2-3 days of starting treatment 1. This profound estrogen suppression is maintained throughout treatment and is highly specific—letrozole does not impair adrenal steroidogenesis or affect production of cortisol, aldosterone, thyroid hormones, or androgens 1.
Importantly, letrozole achieves more complete estrogen suppression than other aromatase inhibitors. Research demonstrates that letrozole reduces residual estradiol to 5.9% (versus 10.1% for anastrozole) and estrone sulfate to 2.0% (versus 4.6% for anastrozole), with significantly more patients achieving estradiol levels below detectable limits 2.
Clinical Benefits Across Treatment Settings
Adjuvant Therapy (After Primary Surgery)
The 2019 ASCO Clinical Practice Guidelines, based on multiple phase III randomized controlled trials, establish letrozole's superior efficacy in the adjuvant setting 3:
- Disease-free survival: Letrozole significantly improves disease-free survival compared to tamoxifen when used as initial adjuvant therapy for 5 years in postmenopausal women with hormone receptor-positive early breast cancer 3
- Treatment outcomes: In Korean postmenopausal women, adjuvant letrozole achieved a 5-year disease-free survival rate of 94.2%, with excellent tolerability 4
- Effectiveness across ER expression levels: Clinical outcomes remain favorable regardless of estrogen receptor expression intensity (low, intermediate, or high), with 5-year disease-free survival rates of 94.3% and 94.1% in low-to-intermediate versus high ER expression groups 4
Extended Adjuvant Therapy
For women who have completed 5 years of endocrine therapy, extending treatment with letrozole provides additional protection against recurrence 3:
- The MA.17R trial demonstrated that letrozole 2.5 mg daily for 5 additional years (after 4.5-6 years of prior aromatase inhibitor therapy) improved outcomes compared to placebo in 1,918 postmenopausal women 3
- The NSABP B-42 study confirmed benefits in 3,923 women who completed 5 years of endocrine therapy 3
- Extended therapy delays time to chemotherapy (40.4 vs 29.9 months) and maintains benefit through subsequent lines of therapy 5
Advanced/Metastatic Disease
In the first-line treatment of hormone receptor-positive advanced breast cancer, letrozole demonstrates superior efficacy 6, 7:
- Significantly better time to progression compared to tamoxifen 7
- Higher response rates and clinical benefit rates than tamoxifen 7
- When combined with palbociclib (a CDK4/6 inhibitor), letrozole achieves median progression-free survival of 27.6 months versus 14.5 months for placebo-letrozole, representing the current standard of care for first-line therapy in ER+/HER2- advanced breast cancer 5
Neoadjuvant Setting (Before Surgery)
Letrozole given for 4 months before surgery results in better overall clinical response and improved breast-conserving surgery rates compared to tamoxifen 6. In a Danish study of 119 postmenopausal women, neoadjuvant letrozole achieved a 15% mean decrease in tumor size, with 55% of patients showing partial pathological response 8. This approach is particularly valuable for patients with highly ER-positive, HER2-negative disease who are not candidates for or do not require chemotherapy 8.
Practical Considerations
Standard dosing: 2.5 mg orally once daily, taken without regard to meals 1
Common adverse effects (occurring in >20% of patients) include 3:
- Hot flashes (38%)
- Arthralgia/joint pain (53%)
- Myalgia/muscle pain (28%)
- Arthritis (33%)
- Fatigue (36%)
- Bone fractures (14% vs 9% placebo, p=0.001) 3
- New osteoporosis (11% vs 6% placebo, p<0.001) 3
Critical monitoring requirements:
- Bone mineral density should be monitored due to increased fracture risk 1
- Cholesterol levels may increase and require monitoring 1
- Patients should be counseled about fatigue, dizziness, and somnolence when operating machinery 1
Important caveat: While musculoskeletal symptoms are common, only about 5.6% of patients discontinue letrozole due to drug toxicity 4. High baseline estradiol levels are associated with increased joint and muscle pain during treatment 9, but this should not preclude therapy given the substantial survival benefits.
The quality of life data from extended trials show that despite these side effects, patients maintain overall quality of life during treatment 3, 5, and the profound reduction in recurrence risk justifies the tolerability profile in most patients.